Skip to main content
Pharos iBio Co., Ltd. logo

Pharos iBio Co., Ltd. — Investor Relations & Filings

Ticker · 388870 ISIN · KR7388870008 KO Professional, scientific and technical activities
Open in API
Filings indexed 83 across all filing types
Latest filing 2025-12-19 Capital/Financing Update
Country KR South Korea
Listing KO 388870

About Pharos iBio Co., Ltd.

https://www.pharosibio.com/en/

Pharos iBio is a clinical-stage biotechnology company that specializes in drug discovery and development. The company leverages a proprietary platform based on artificial intelligence (AI) and big data to identify and create novel therapeutic candidates. Its primary focus is on developing treatments for rare and refractory diseases, with a significant emphasis on oncology. The development pipeline includes assets that are progressing through clinical trials, such as a therapy for acute myeloid leukemia.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시) (제1회차 CB)
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Issuance Result' (증권 발행결과) filing from Pharos iBio, detailing the completion of a private convertible bond issuance. It specifies the type of security, the amount issued (19 billion KRW), and the payment date. This falls under the category of capital structure changes and financing activities, specifically matching the 'Share Issue/Capital Change' (SHA) category as it relates to the issuance of convertible securities.
2025-12-19 Korean
분기보고서 (2025.09)
Regulatory Filings
2025-11-11 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Pharos iBio' (파로스아이바이오) covering the period from January 1, 2025, to June 30, 2025. It contains detailed business information, pipeline status, and management discussions, which are characteristic of an interim/quarterly financial report. It is not a mere announcement (RPA) as it contains substantive operational and financial data. H1 2025
2025-08-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details a specific transaction (a purchase of shares) by an executive (Kim Kyu Tae) of Pharos iBio. This type of filing is a standard regulatory disclosure for insider trading/director dealings.
2025-07-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Yoon Jeong Hyeok) of Pharos iBio. This type of filing, which discloses changes in share ownership by company insiders, corresponds to the 'Director's Dealing' category in the provided classification schema.
2025-07-16 Korean
투자판단관련주요경영사항(임상시험결과) (경구용 항암제 PHI101의 임상 1상 임상시험결과보고서(CSR) 수령)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure filed by a company (Pharos iBio) regarding the receipt of a Clinical Study Report (CSR) for a Phase 1 clinical trial. It details the trial methodology, safety results, and efficacy findings. Since this is a mandatory disclosure of material business information regarding clinical trial results to regulatory authorities (such as the KRX in Korea), it falls under the category of Regulatory Filings (RNS), as it does not fit into specific categories like Earnings Release or Annual Report.
2025-06-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.